ICON Public Limited Company (ICLR)
USD 204.4
(0.56%)
USD 204.4
(0.56%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 612.33 Million USD | 21.18% |
| 2022 | 505.3 Million USD | 229.87% |
| 2021 | 153.18 Million USD | -53.27% |
| 2020 | 327.8 Million USD | -12.35% |
| 2019 | 373.98 Million USD | 15.85% |
| 2018 | 322.81 Million USD | 18.27% |
| 2017 | 272.94 Million USD | 4.11% |
| 2016 | 262.17 Million USD | 9.45% |
| 2015 | 239.53 Million USD | 38.89% |
| 2014 | 172.46 Million USD | 67.75% |
| 2013 | 102.81 Million USD | 76.21% |
| 2012 | 58.34 Million USD | 155.01% |
| 2011 | 22.88 Million USD | -73.72% |
| 2010 | 87.07 Million USD | -7.66% |
| 2009 | 94.29 Million USD | 20.71% |
| 2008 | 78.12 Million USD | 39.59% |
| 2007 | 55.96 Million USD | 46.1% |
| 2006 | 38.3 Million USD | 0.0% |
| 2005 | - USD | -100.0% |
| 2004 | 25.74 Million USD | 40.8% |
| 2003 | 18.28 Million USD | 28.75% |
| 2002 | 14.2 Million USD | 29.35% |
| 2001 | 10.97 Million USD | 80.92% |
| 2000 | 6.06 Million USD | -19.09% |
| 1999 | 7.5 Million USD | 92.31% |
| 1998 | 3.9 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 197.12 Million USD | 34.18% |
| 2024 Q2 | 146.91 Million USD | -21.62% |
| 2024 Q1 | 187.43 Million USD | -13.39% |
| 2023 Q1 | 116.65 Million USD | -0.67% |
| 2023 FY | 612.33 Million USD | 21.18% |
| 2023 Q4 | 216.41 Million USD | 32.23% |
| 2023 Q2 | 115.59 Million USD | -0.91% |
| 2023 Q3 | 163.66 Million USD | 41.58% |
| 2022 FY | 505.3 Million USD | 229.87% |
| 2022 Q1 | 111.97 Million USD | 46.43% |
| 2022 Q2 | 115.73 Million USD | 3.36% |
| 2022 Q3 | 160.15 Million USD | 38.38% |
| 2022 Q4 | 117.44 Million USD | -26.67% |
| 2021 FY | 153.18 Million USD | -53.27% |
| 2021 Q1 | 97.12 Million USD | -4.06% |
| 2021 Q4 | 76.46 Million USD | 181.12% |
| 2021 Q3 | -94.27 Million USD | -227.62% |
| 2021 Q2 | 73.86 Million USD | -23.95% |
| 2020 Q4 | 101.23 Million USD | 10.47% |
| 2020 Q3 | 91.64 Million USD | 91.88% |
| 2020 FY | 327.8 Million USD | -12.35% |
| 2020 Q2 | 47.76 Million USD | -47.91% |
| 2020 Q1 | 91.69 Million USD | -7.38% |
| 2019 Q2 | 91.85 Million USD | 4.03% |
| 2019 Q1 | 88.29 Million USD | 0.15% |
| 2019 Q3 | 94.82 Million USD | 3.23% |
| 2019 FY | 373.98 Million USD | 15.85% |
| 2019 Q4 | 99 Million USD | 4.41% |
| 2018 Q2 | 71.86 Million USD | -7.98% |
| 2018 FY | 322.81 Million USD | 18.27% |
| 2018 Q3 | 84.52 Million USD | 17.61% |
| 2018 Q4 | 88.16 Million USD | 4.3% |
| 2018 Q1 | 78.09 Million USD | 9.83% |
| 2017 Q3 | 74.15 Million USD | 14.41% |
| 2017 Q2 | 64.81 Million USD | -9.23% |
| 2017 Q1 | 71.4 Million USD | -3.84% |
| 2017 FY | 272.94 Million USD | 4.11% |
| 2017 Q4 | 71.1 Million USD | -4.11% |
| 2016 Q4 | 74.26 Million USD | 16.25% |
| 2016 Q3 | 63.87 Million USD | 4.59% |
| 2016 Q1 | 62.96 Million USD | -0.73% |
| 2016 FY | 262.17 Million USD | 9.45% |
| 2016 Q2 | 61.07 Million USD | -3.0% |
| 2015 Q1 | 55.86 Million USD | 23.68% |
| 2015 Q3 | 61.54 Million USD | 5.05% |
| 2015 FY | 239.53 Million USD | 38.89% |
| 2015 Q4 | 63.42 Million USD | 3.07% |
| 2015 Q2 | 58.58 Million USD | 4.86% |
| 2014 Q1 | 36.19 Million USD | 8.11% |
| 2014 FY | 172.46 Million USD | 67.75% |
| 2014 Q4 | 45.17 Million USD | -10.22% |
| 2014 Q2 | 40.78 Million USD | 12.68% |
| 2014 Q3 | 50.31 Million USD | 23.37% |
| 2013 Q4 | 33.48 Million USD | 20.4% |
| 2013 Q3 | 27.8 Million USD | 23.71% |
| 2013 Q2 | 22.47 Million USD | 18.03% |
| 2013 FY | 102.81 Million USD | 76.21% |
| 2013 Q1 | 19.04 Million USD | -8.2% |
| 2012 Q1 | 8.97 Million USD | 118.11% |
| 2012 Q2 | 7.96 Million USD | -11.23% |
| 2012 Q3 | 17.73 Million USD | 122.73% |
| 2012 Q4 | 20.74 Million USD | 16.96% |
| 2012 FY | 58.34 Million USD | 155.01% |
| 2011 Q2 | 13.08 Million USD | 56.71% |
| 2011 Q4 | 4.11 Million USD | 254.45% |
| 2011 Q3 | -2.66 Million USD | -120.36% |
| 2011 FY | 22.88 Million USD | -73.72% |
| 2011 Q1 | 8.34 Million USD | -62.23% |
| 2010 Q3 | 19.89 Million USD | -13.0% |
| 2010 Q2 | 22.87 Million USD | 3.04% |
| 2010 Q1 | 22.19 Million USD | -28.1% |
| 2010 FY | 87.07 Million USD | -7.66% |
| 2010 Q4 | 22.1 Million USD | 11.06% |
| 2009 Q4 | 30.87 Million USD | 28.9% |
| 2009 Q1 | 20.94 Million USD | -0.39% |
| 2009 FY | 94.29 Million USD | 20.71% |
| 2009 Q3 | 23.95 Million USD | 5.25% |
| 2009 Q2 | 22.75 Million USD | 8.66% |
| 2008 Q1 | 16.89 Million USD | 6.38% |
| 2008 FY | 78.12 Million USD | 39.59% |
| 2008 Q4 | 21.02 Million USD | -1.66% |
| 2008 Q3 | 21.38 Million USD | 13.6% |
| 2008 Q2 | 18.82 Million USD | 11.41% |
| 2007 Q3 | 14.5 Million USD | 8.91% |
| 2007 FY | 55.96 Million USD | 46.1% |
| 2007 Q1 | 12.26 Million USD | 7.86% |
| 2007 Q4 | 15.88 Million USD | 9.52% |
| 2007 Q2 | 13.31 Million USD | 8.55% |
| 2006 FY | 38.3 Million USD | 0.0% |
| 2006 Q3 | 10.09 Million USD | 8.57% |
| 2006 Q4 | 11.37 Million USD | 12.66% |
| 2006 Q1 | 7.54 Million USD | 8.46% |
| 2006 Q2 | 9.29 Million USD | 23.29% |
| 2005 Q4 | 6.95 Million USD | 8.93% |
| 2005 FY | - USD | -100.0% |
| 2005 Q1 | -5.52 Million USD | -195.0% |
| 2005 Q2 | 5.94 Million USD | 207.62% |
| 2005 Q3 | 6.38 Million USD | 7.3% |
| 2004 FY | 25.74 Million USD | 40.8% |
| 2004 Q2 | 7.22 Million USD | 8.59% |
| 2004 Q3 | 7.3 Million USD | 1.15% |
| 2004 Q4 | 5.81 Million USD | -20.34% |
| 2004 Q1 | 6.65 Million USD | 6.16% |
| 2003 Q1 | 4.59 Million USD | 4.03% |
| 2003 FY | 18.28 Million USD | 28.75% |
| 2003 Q4 | 6.26 Million USD | 11.8% |
| 2003 Q3 | 5.6 Million USD | 5.86% |
| 2003 Q2 | 5.29 Million USD | 15.16% |
| 2002 Q4 | 4.41 Million USD | 11.23% |
| 2002 FY | 14.2 Million USD | 29.35% |
| 2002 Q2 | 3.81 Million USD | 6.03% |
| 2002 Q1 | 3.59 Million USD | 4.08% |
| 2002 Q3 | 3.97 Million USD | 4.14% |
| 2001 Q3 | 3.33 Million USD | 9.11% |
| 2001 Q1 | 2.78 Million USD | 4.86% |
| 2001 Q4 | 3.45 Million USD | 3.81% |
| 2001 Q2 | 3.05 Million USD | 9.71% |
| 2001 FY | 10.97 Million USD | 80.92% |
| 2000 Q3 | 2.49 Million USD | 6.45% |
| 2000 Q4 | 2.65 Million USD | 6.5% |
| 2000 Q2 | 2.34 Million USD | 19400.0% |
| 2000 Q1 | 12 Thousand USD | -99.37% |
| 2000 FY | 6.06 Million USD | -19.09% |
| 1999 Q4 | 1.9 Million USD | 18.75% |
| 1999 FY | 7.5 Million USD | 92.31% |
| 1999 Q2 | 1.6 Million USD | -23.81% |
| 1999 Q1 | 2.1 Million USD | 10.53% |
| 1999 Q3 | 1.6 Million USD | 0.0% |
| 1998 Q4 | 1.9 Million USD | 0.0% |
| 1998 Q2 | 1.2 Million USD | 33.33% |
| 1998 Q1 | 900 Thousand USD | 0.0% |
| 1998 FY | 3.9 Million USD | 0.0% |
| 1998 Q3 | 1.9 Million USD | 58.33% |
| 1997 Q4 | 900 Thousand USD | 0.0% |
| 1997 Q3 | 900 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bionano Genomics, Inc. | -232.49 Million USD | 363.378% |
| Prenetics Global Limited | -62.72 Million USD | 1076.239% |
| Star Equity Holdings, Inc. | -1.54 Million USD | 39656.525% |
| CareDx, Inc | -190.28 Million USD | 421.801% |
| Exact Sciences Corporation | -204.14 Million USD | 399.945% |
| Exagen Inc. | -23.68 Million USD | 2684.892% |
| Inotiv, Inc. | -105.14 Million USD | 682.4% |
| Guardant Health, Inc. | -479.44 Million USD | 227.716% |
| Biodesix, Inc. | -52.14 Million USD | 1274.27% |
| BioNexus Gene Lab Corp. | -2.62 Million USD | 23391.175% |
| Precipio, Inc. | -5.85 Million USD | 10561.9% |
| iSpecimen Inc. | -11.09 Million USD | 5616.786% |
| Natera, Inc. | -434.8 Million USD | 240.831% |
| Aspira Women's Health Inc. | -16.69 Million USD | 3768.874% |
| Standard BioTools Inc. | -74.65 Million USD | 920.209% |
| 23andMe Holding Co. | -666.7 Million USD | 191.845% |
| Castle Biosciences, Inc. | -57.46 Million USD | 1165.561% |
| Personalis, Inc. | -108.29 Million USD | 665.427% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 792.053% |
| Applied DNA Sciences, Inc. | -9.94 Million USD | 6255.94% |
| OpGen, Inc. | -32.66 Million USD | 1974.388% |
| T2 Biosystems, Inc. | -50.07 Million USD | 1322.787% |
| Myriad Genetics, Inc. | -112 Million USD | 646.728% |
| NeoGenomics, Inc. | -87.96 Million USD | 796.088% |
| Star Equity Holdings, Inc. | -1.54 Million USD | 39656.525% |
| IDEXX Laboratories, Inc. | 845.04 Million USD | 27.538% |
| RadNet, Inc. | 3.04 Million USD | -20016.13% |
| MDxHealth SA | -43.1 Million USD | 1520.731% |
| Psychemedics Corporation | -4.15 Million USD | 14840.852% |
| Illumina, Inc. | -1.16 Billion USD | 152.742% |
| Check-Cap Ltd. | -17.56 Million USD | 3585.513% |
| Twist Bioscience Corporation | -208.72 Million USD | 393.368% |
| DarioHealth Corp. | -59.42 Million USD | 1130.399% |
| Fulgent Genetics, Inc. | -167.82 Million USD | 464.865% |
| Sera Prognostics, Inc. | -36.24 Million USD | 1789.573% |
| ENDRA Life Sciences Inc. | -10.06 Million USD | 6186.678% |
| OPKO Health, Inc. | -188.86 Million USD | 424.222% |
| Medpace Holdings, Inc. | 282.81 Million USD | -116.518% |
| Neogen Corporation | -9.42 Million USD | 6599.682% |
| Intelligent Bio Solutions Inc. | -10.15 Million USD | 6128.842% |
| Prenetics Global Limited | -62.72 Million USD | 1076.239% |
| Mainz Biomed B.V. | -26.29 Million USD | 2428.648% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | 7814.932% |
| Trinity Biotech plc | -24.01 Million USD | 2649.484% |
| Neuronetics, Inc. | -30.18 Million USD | 2128.338% |
| Sotera Health Company | 51.37 Million USD | -1091.87% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | 7814.932% |